

# MDS-SPONSORED REVISION OF THE UNIFIED PARKINSON'S DISEASE RATING SCALE (MDS-UPDRS)

EUROPEAN REFERENCE NETWORKS  
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

**Share. Care. Cure.**



## Disclaimer:

“The European Commission support for the production of this publication does not constitute endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.”

More information on the European Union is available on the Internet (<http://europa.eu>).

Luxembourg: Publications Office of the European Union, 2019

© European Union, 2019

Reproduction is authorised provided the source is acknowledged.

## INTRODUCTION TO THE EUROPEAN REFERENCE NETWORK FOR RARE NEUROLOGICAL DISEASES (ERN-RND)

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 64 of Europe's leading expert centers as well as 4 affiliated partners in 24 member states and includes highly active patient organizations. Centers are located in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Slovenia, Spain and Sweden.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinson's disease
- Dystonia, Paroxysmal Disorder and Neurodegeneration with Brain Iron Accumulation
- Frontotemporal Dementia
- Huntington's Disease and other Chorea
- Leukodystrophies

Specific information about the network, the expert centers and the covered diseases can be found on the network's website [www.ern-rnd.eu](http://www.ern-rnd.eu).

### **Recommendation for clinical use:**

**The European Reference Network for Rare Neurological Diseases recommends the use of the MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) as best clinical practice for the assessment and rating of genetic Parkinson's disease.**

## DISCLAIMER

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service.

The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose.

ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

## METHODOLOGY

The endorsement process has been performed by the Disease group for Atypical Parkinsonism and Genetic PD of ERN-RND.

## Disease group for Atypical Parkinsonism and Genetic PD:

### Disease group coordinators:

Alessandra Fanciulli<sup>29</sup>; Pietro Guaraldi<sup>24</sup>; Johannes Levin<sup>28</sup>

### Disease group members:

#### Health care professionals:

Albert Acewicz<sup>21</sup>; Archontia Adamou<sup>13</sup>; Alberto Albanese<sup>23</sup>; Angelo Antonini<sup>4</sup>; David Bendetowicz<sup>12</sup>; Martina Bočková<sup>37</sup>; Daniel Boesch<sup>29</sup>; Agnita Boon<sup>15</sup>; Fran Borovečki<sup>41</sup>; Norbert Brüggemann<sup>44</sup>; Giovanna Calandra Buonaura<sup>24</sup>; Myriam Carrecchio<sup>4</sup>; Fátima Carrillo García<sup>51</sup>; Roberto Ceravolo<sup>5</sup>; Roberto Cilia<sup>22</sup>; Colin Clarke<sup>25</sup>; Yaroslau Compta<sup>20</sup>; David Crosiers<sup>2</sup>; Erik Hvid Danielsen<sup>1</sup>; Sára Davisonová<sup>17</sup>; Oriol de Fabregues<sup>50</sup>; Anna De Rosa<sup>3</sup>; Małgorzata Dec-Ćwie<sup>42</sup>; Eleonora Del Prete<sup>5</sup>; Elisa Dopper<sup>15</sup>; Roberto Eleopra<sup>22</sup>; Antonio Elia<sup>22</sup>; Marta Blázquez Estrada<sup>8</sup>; Claire Ewencyk<sup>7</sup>; Margherita Fabbri<sup>11</sup>; Antonio Federico<sup>6</sup>; Daniela Frosini<sup>5</sup>; Barbara Garavaglia<sup>22</sup>; Rocio Garcia Ramos<sup>35</sup>; Giacomo Garone<sup>31</sup>; Thomas Gasser<sup>45</sup>; Beatrice Heim<sup>29</sup>; Lena Hjermind<sup>33</sup>; Günter Höglinger<sup>28</sup>; Florian Holtbernd<sup>34</sup>; Franziska Höpfner<sup>28</sup>; Silvia Jesús<sup>51</sup>; Erik Johnsen<sup>1</sup>; Liis Kadastik-Eerme<sup>39</sup>; Christine Klein<sup>44</sup>; Jiří Klempíř<sup>17</sup>; Martin Klietz<sup>19</sup>; Péter Klivényi<sup>38</sup>; Thomas Klopstock<sup>28</sup>; Maija Koivu<sup>16</sup>; Maja Kojović<sup>48</sup>; Pierre Kolber<sup>10</sup>; Vassilis Konstantinidis<sup>14</sup>; Christos Koros<sup>14</sup>; Norbert Kovács<sup>49</sup>; Florian Krismer<sup>29</sup>; Bernhard Landwehrmeier<sup>46</sup>; Krista Lazdovska<sup>30</sup>; Valentina Leta<sup>22</sup>; Gerrit Machetanz<sup>45</sup>; Virginia Maltese<sup>47</sup>; Maria Jose Martí<sup>20</sup>; Allan McCarthy<sup>25</sup>; Wassilios Meissner<sup>12</sup>; Andrea Mignarri<sup>6</sup>; Pablo Mir<sup>51</sup>; Maria Judit Molnar<sup>36</sup>; Mette Møller<sup>1</sup>; Laura Muñoz<sup>51</sup>; Thomas Musacchio Musacchio<sup>47</sup>; Francesco Nicita<sup>31</sup>; Joergen Nielsen<sup>33</sup>; Sean O'Dowd<sup>25</sup>; Elena Ojeda Lepe<sup>51</sup>; Marios Pantzaris<sup>13</sup>; Anne Pavy-Le Traon<sup>11</sup>; Javier Perez Sanchez<sup>18</sup>; Bart Post<sup>32</sup>; Irena Rektorova<sup>37</sup>; Ana Rodríguez<sup>27</sup>; Evžen Růžička<sup>17</sup>; Katarzyna Sawczynska<sup>42</sup>; Soledad Serrano<sup>27</sup>; Leonidas Stefanis<sup>14</sup>; Per Svenningsson<sup>26</sup>; Lars Toenges<sup>9</sup>; Marzena Ulamek-Kozioł<sup>21</sup>; Ramona Valante<sup>30</sup>; Francesc Valldeoriola<sup>20</sup>; Wim Vandenberghe<sup>43</sup>; Richard Walsh<sup>25</sup>; Ullrich Wüllner<sup>40</sup>; Emil Ylikallio<sup>16</sup>

#### Patient representative:

Lubomír Mazouch<sup>52</sup>

<sup>1</sup>Aarhus University Hospital, Denmark; <sup>2</sup>Antwerp University Hospital, Edegem, Belgium; <sup>3</sup>AOU - Federico II University Hospital, Naples, Italy; <sup>4</sup>AOU - University Hospital Padua, Italy; <sup>5</sup>AOU - University Hospital Pisa, Italy; <sup>6</sup>AOU - University Hospital Siena, Italy; <sup>7</sup>APHP - Reference Centre for Rare Diseases 'Neurogenetics', Pitié-Salpêtrière Hospital, Paris, France; <sup>8</sup>Asturias Central University Hospital, Oviedo, Spain; <sup>9</sup>Catholic Clinic Bochum, Germany; <sup>10</sup>CHL - Luxembourg Hospital Center, Luxembourg; <sup>11</sup>CHU - Reference Center for Rare Multiple System Atrophy diseases, University Hospital Toulouse, France; <sup>12</sup>CHU - Reference Center for Rare Multiple System Atrophy, University Hospital Bordeaux, France; <sup>13</sup>Cyprus Institute of Neurology and Genetics, Egkomi, Cyprus; <sup>14</sup>Eginitio Hospital, National and Kapodistrian University of Athens, Greece; <sup>15</sup>Erasmus University Medical Center Rotterdam, Netherlands; <sup>16</sup>Finland Consortium: University Hospitals in Oulu, Tampere and Helsinki, Finland; <sup>17</sup>General University Hospital Prague, Czech Republic; <sup>18</sup>Gregorio Marañón General University Hospital, Madrid, Spain; <sup>19</sup>Hannover Medical School, Germany; <sup>20</sup>Hospital Clinic Barcelona and Sant Joan de Déu Hospital, Barcelona, Spain; <sup>21</sup>Institute of Psychiatry

and Neurology, Warsaw, Poland; <sup>22</sup>IRCCS - Foundation of the Carlo Besta Neurological Institute, Milan, Italy; <sup>23</sup>IRCCS - Humanitas Clinical Institute of Rozzano, Milan, Italy; <sup>24</sup>IRCCS - Institute of Neurological Sciences of Bologna, Italy; <sup>25</sup>Irish Consortium: Tallaght University Hospital and Children's Health Ireland; <sup>26</sup>Karolinska University Hospital, Stockholm, Sweden; <sup>27</sup>La Paz University Hospital, Madrid, Spain; <sup>28</sup>Ludwig Maximilian University Hospital, Munich, Germany; <sup>29</sup>Medical University Innsbruck, Austria; <sup>30</sup>Pauls Stradins Clinical University Hospital, Riga, Latvia; <sup>31</sup>Pediatric Hospital Bambino Gesù, Rome, Italy; <sup>32</sup>Radboud University Medical Centre, Nijmegen, Netherlands; <sup>33</sup>Rigshospitalet University Hospital Copenhagen, Denmark; <sup>34</sup>RWTH - University Hospital Aachen, Germany; <sup>35</sup>San Carlos Clinical Hospital, Madrid, Spain; <sup>36</sup>Semmelweis University, Budapest, Hungary; <sup>37</sup>St. Anne's University Hospital Brno, Czech Republic; <sup>38</sup>Szent-Györgyi Albert Medical Center, Szeged, Hungary; <sup>39</sup>Tartu University Hospital, Estonia; <sup>40</sup>University Hospital Bonn, Germany; <sup>41</sup>University Hospital Center Zagreb, Croatia; <sup>42</sup>University Hospital in Krakow, Poland; <sup>43</sup>University Hospital Leuven, Belgium; <sup>44</sup>University Hospital Schleswig-Holstein, Lübeck, Germany; <sup>45</sup>University Hospital Tübingen, Germany; <sup>46</sup>University Hospital Ulm, Germany; <sup>47</sup>University Hospital Würzburg, Germany; <sup>48</sup>University Medical Centre Ljubljana, Slovenia; <sup>49</sup>University of Pécs, Hungary; <sup>50</sup>Vall d'Hebron University Hospital, Barcelona, Spain; <sup>51</sup>Virgen del Rocio University Hospital, Sevilla, Spain; <sup>52</sup>ePAG

## Endorsement process:

- Mapping of used disease scales by disease group: June 2017– May 2018
- Proposal for endorsement of rating scale by ERN-RND disease group coordinators: 15/05/2018
- Discussion in ERN-RND disease group during annual meeting: 08/06/2018
- Consent on endorsement of disease scale during ERN-RND annual meeting 2018: 08/06/2018
- Consent on endorsement by whole disease group: 25/09/2018
- Endorsement of updated document: 11/10/2024

## REFERENCES

### **MDS Unified Parkinsons Disease Rating Scale:**

<https://www.movementdisorders.org/MDS/MDS-Rating-Scales/MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-UPDRS.htm>

### **Hoehn & Yahr Rating Scale:**

<https://www.neurology.org/doi/abs/10.1212/wnl.17.5.427>



[https://ec.europa.eu/health/ern\\_en](https://ec.europa.eu/health/ern_en)



European  
Reference  
Network

for rare or low prevalence  
complex diseases

Network  
Neurological Diseases  
(ERN-RND)

Coordinator  
Universitätsklinikum  
Tübingen – Deutschland

[www.ern-rnd.eu](http://www.ern-rnd.eu)

Co-funded by the European Union

